CFTR mRNA-Based Gene Therapy for Cystic Fibrosis: A Mutation-Agnostic Strategy to Restore Ion Transport Function

Area of Science:

• Biotechnology
• Genetic Medicine
• Pulmonology

Background:

• Cystic fibrosis (CF) is a genetic disorder caused by CFTR gene mutations, leading to mucus buildup and organ damage.
• Current CFTR modulators benefit only specific mutations, necessitating broader therapeutic strategies.
• CFTR-mRNA therapy presents a mutation-independent approach to restore chloride ion transport.

Purpose of the Study:

• To evaluate the potential of CFTR-mRNA-based gene therapy for treating cystic fibrosis.
• To assess the efficacy and delivery methods of synthetic CFTR mRNA in restoring epithelial cell function.
• To review current advancements and future directions in CFTR-mRNA therapy.

Main Methods:

• Delivery of synthetic CFTR mRNA to epithelial cells using non-viral carriers like lipid nanoparticles.
• Assessment of CFTR protein synthesis and restoration of ion transport in preclinical models.
• Evaluation of airway hydration and functional outcomes in animal models of CF.

Main Results:

• Successful restoration of CFTR function and improved airway hydration observed in animal studies.
• mRNA therapy demonstrated potential for universal application across various CFTR mutations.
• Non-viral delivery systems showed promise in protecting mRNA and enhancing cellular uptake.

Conclusions:

• CFTR-mRNA therapy is a promising, mutation-independent treatment strategy for cystic fibrosis.
• Advancements in mRNA engineering and delivery technologies are crucial for overcoming challenges like instability and immunogenicity.
• This approach holds potential for a single, comprehensive treatment for all CF patients.